Nasdaq · CIK 0001623526
STOK Stoke Therapeutics, Inc.
Insider trading from SEC Form 4. Last filing 10 d ago. Close $24.74 on Oct 9, 2026, +11% from the 52-week low and -35% from the high.
Last 90 days
Net insider value
-$214k
more sold than bought
Buys
0
$0 by 0 insiders
Sells
3
$214k by 2 insiders
Insiders on file
11
with a Form 4 at this company
Price and insider trades, last year
STOKOct 9, 2026 · close 24.74
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Stoke Therapeutics, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 3Weak | Jonathan Allan GENERAL COUNSEL & CORP SEC sell | $17k 627 shares | -3% | +15% from low-33% from high | |
| 8Weak | Barry Ticho CHIEF MEDICAL OFFICER sell | $27k 1,051 shares | -5% | +16% from low-32% from high | |
| 11Weak | Barry Ticho CHIEF MEDICAL OFFICER sell | $170k 5,545 shares | -22% | +58% from low-19% from high | |
| 17Weak | Jonathan Allan GENERAL COUNSEL & CORP SEC sell | $445k 22,117 shares | -89% | +235% from low-0% from high | |
| 20Weak | Jonathan Allan GENERAL COUNSEL & CORP SEC sell | $31k 1,683 shares | -7% | +214% from low0% from high | |
| 17Weak | Jonathan Allan GENERAL COUNSEL & CORP SEC sell | $206k 13,712 shares | -41% | +187% from low0% from high | |
| 55Moderate | Skorpios Trust owner sell | $31M 3,000,000 shares | -43% | +85% from low-28% from high | |
| 17Weak | Barry Ticho CHIEF MEDICAL OFFICER sell | $82k 8,216 shares | -24% | +68% from low-35% from high | |
| 18Weak | Barry Ticho CHIEF MEDICAL OFFICER sell | $267k 26,631 shares | -44% | +67% from low-35% from high | |
| 34Weak | Jonathan Allan GENERAL COUNSEL & CORP SEC sell | $36k 4,211 shares | -12% | +20% from low-42% from high | |
| 39Weak | Edward M. Kaye MD CEO sell | $164k 19,289 shares | -12% | +20% from low-42% from high | |
| 57Moderate | Skorpios Trust owner sell | $23M 2,000,000 shares | -22% | +5% from low-24% from high | |
| 32Weak | Jonathan Allan GENERAL COUNSEL & CORP SEC sell | $186k 13,666 shares | -39% | +22% from low-10% from high | |
| 49Moderate | Edward M. Kaye MD CEO sell | $88k 6,786 shares | -10% | +22% from low-10% from high | |
| 36Weak | Barry Ticho CHIEF MEDICAL OFFICER sell | $34k 2,586 shares | -5% | +22% from low-10% from high | |
| 45Moderate | Jonathan Allan GENERAL COUNSEL & CORP SEC sell | $124k 9,696 shares | -22% | +18% from low-13% from high | |
| 49Moderate | Edward M. Kaye MD CEO sell | $79k 6,170 shares | -8% | +18% from low-13% from high | |
| 47Moderate | Barry Ticho CHIEF MEDICAL OFFICER sell | $178k 13,945 shares | -23% | +18% from low-13% from high | |
| 10Weak | Barry Ticho CHIEF MEDICAL OFFICER sell | $121k 10,000 shares | -16% | +7% from low-21% from high | |
| 11Weak | Barry Ticho CHIEF MEDICAL OFFICER sell | $127k 10,000 shares | -80% | +13% from low-16% from high |
Transactions
The last 81 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 1, 2026 | Barry Ticho CHIEF MEDICAL OFFICER | SOpen-market sale Common Stock10b5-1 | -1,051 | $26.16 | $27k | 19,059 | 10 d ago |
| Oct 2, 2026 | Jonathan Allan GENERAL COUNSEL & CORP SEC | SOpen-market sale Common Stock10b5-1 | -627 | $26.33 | $17k | 20,598 | 10 d ago |
| Sep 23, 2026 | Alexander Cumbo director | AGrant or award Director Stock Option (Right to Buy)derivative | +39,674 | $0.00 | $0 | 39,674 | 17 d ago |
| Sep 1, 2026 | Barry Ticho CHIEF MEDICAL OFFICER | SOpen-market sale Common Stock10b5-1 | -3,945 | $30.51 | $120k | 21,710 | 39 d ago |
| Sep 1, 2026 | Barry Ticho CHIEF MEDICAL OFFICER | SOpen-market sale Common Stock10b5-1 | -1,600 | $31.06 | $50k | 20,110 | 39 d ago |
| Aug 29, 2025 | Jonathan Allan GENERAL COUNSEL & CORP SEC | MOption exercise Common Stock10b5-1 | +850 | $7.07 | $6,010 | 24,798 | Sep 3, 2025 |
| Aug 29, 2025 | Jonathan Allan GENERAL COUNSEL & CORP SEC | SOpen-market sale Common Stock10b5-1 | -850 | $20.00 | $17k | 23,948 | Sep 3, 2025 |
| Sep 2, 2025 | Jonathan Allan GENERAL COUNSEL & CORP SEC | MOption exercise Common Stock10b5-1 | +9,150 | $7.07 | $65k | 33,098 | Sep 3, 2025 |
| Sep 2, 2025 | Jonathan Allan GENERAL COUNSEL & CORP SEC | SOpen-market sale Common Stock10b5-1 | -14,922 | $20.14 | $300k | 18,176 | Sep 3, 2025 |
| Sep 3, 2025 | Jonathan Allan GENERAL COUNSEL & CORP SEC | SOpen-market sale Common Stock10b5-1 | -6,345 | $20.07 | $127k | 11,831 | Sep 3, 2025 |
| Aug 29, 2025 | Jonathan Allan GENERAL COUNSEL & CORP SEC | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -850 | $0.00 | $0 | 24,951 | Sep 3, 2025 |
| Sep 2, 2025 | Jonathan Allan GENERAL COUNSEL & CORP SEC | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -9,150 | $0.00 | $0 | 15,801 | Sep 3, 2025 |
| Aug 18, 2025 | Jonathan Allan GENERAL COUNSEL & CORP SEC | SOpen-market sale Common Stock | -1,683 | $18.24 | $31k | 23,948 | Aug 20, 2025 |
| Aug 14, 2025 | Jonathan Allan GENERAL COUNSEL & CORP SEC | MOption exercise Common Stock | +6,000 | $0.00 | $0 | 25,631 | Aug 18, 2025 |
| Aug 14, 2025 | Jonathan Allan GENERAL COUNSEL & CORP SEC | AGrant or award Performance Stock Unitsderivative | +12,000 | $0.00 | $0 | 12,000 | Aug 18, 2025 |
| Aug 14, 2025 | Jonathan Allan GENERAL COUNSEL & CORP SEC | MOption exercise Performance Stock Unitsderivative | -6,000 | $0.00 | $0 | 6,000 | Aug 18, 2025 |
| Aug 13, 2025 | Jonathan Allan GENERAL COUNSEL & CORP SEC | SOpen-market sale Common Stock10b5-1 | -13,712 | $15.00 | $206k | 19,631 | Aug 15, 2025 |
| Jun 4, 2025 | Skorpios Trust owner | SOpen-market sale Common Stockindirect: See Footnote | -3,000,000 | $10.20 | $31M | 3,906,181 | Jun 6, 2025 |
| Jun 3, 2025 | Arthur A Levin director | AGrant or award Director Stock Option (Right to Buy)derivative | +29,747 | $0.00 | $0 | 29,747 | Jun 4, 2025 |
| Jun 2, 2025 | Barry Ticho CHIEF MEDICAL OFFICER | SOpen-market sale Common Stock10b5-1 | -1,745 | $10.00 | $17k | 32,253 | Jun 4, 2025 |
| Jun 3, 2025 | Julie Smith director | AGrant or award Director Stock Option (Right to Buy)derivative | +29,747 | $0.00 | $0 | 29,747 | Jun 4, 2025 |
| Jun 3, 2025 | Garry E Menzel director | AGrant or award Director Stock Option (Right to Buy)derivative | +29,747 | $0.00 | $0 | 29,747 | Jun 4, 2025 |
| Jun 3, 2025 | Adrian R. Krainer director | AGrant or award Director Stock Option (Right to Buy)derivative | +29,747 | $0.00 | $0 | 29,747 | Jun 4, 2025 |
| Jun 3, 2025 | Seth Loring Harrison director | AGrant or award Director Stock Option (Right to Buy)derivative | +29,747 | $0.00 | $0 | 29,747 | Jun 4, 2025 |
| Jun 3, 2025 | Jennifer Burstein director | AGrant or award Director Stock Option (Right to Buy)derivative | +29,747 | $0.00 | $0 | 29,747 | Jun 4, 2025 |
| Jun 3, 2025 | Barry Ticho CHIEF MEDICAL OFFICER | SOpen-market sale Common Stock10b5-1 | -6,471 | $10.03 | $65k | 25,782 | Jun 4, 2025 |
| May 1, 2025 | Barry Ticho CHIEF MEDICAL OFFICER | SOpen-market sale Common Stock10b5-1 | -3,841 | $10.00 | $38k | 56,788 | May 5, 2025 |
| May 2, 2025 | Barry Ticho CHIEF MEDICAL OFFICER | SOpen-market sale Common Stock10b5-1 | -22,790 | $10.03 | $229k | 33,998 | May 5, 2025 |
| Mar 31, 2025 | Arthur A Levin director | MOption exercise Common Stock | +1,210 | $0.00 | $0 | 1,210 | Apr 2, 2025 |
| Mar 31, 2025 | Arthur A Levin director | MOption exercise Restricted Stock Unitsderivative | -1,210 | $0.00 | $0 | 3,632 | Apr 2, 2025 |
| Mar 18, 2025 | Edward M. Kaye MD CEO | SOpen-market sale Common Stock | -10,382 | $8.67 | $90k | 148,253 | Mar 20, 2025 |
| Mar 18, 2025 | Jonathan Allan GENERAL COUNSEL & CORP SEC | SOpen-market sale Common Stock | -2,266 | $8.67 | $20k | 33,510 | Mar 20, 2025 |
| Mar 19, 2025 | Arthur A Levin director | AGrant or award Restricted Stock Unitsderivative | +4,842 | $0.00 | $0 | 4,842 | Mar 20, 2025 |
| Mar 19, 2025 | Jonathan Allan GENERAL COUNSEL & CORP SEC | SOpen-market sale Common Stock | -1,945 | $8.27 | $16k | 31,565 | Mar 20, 2025 |
| Mar 19, 2025 | Edward M. Kaye MD CEO | SOpen-market sale Common Stock | -8,907 | $8.27 | $74k | 139,346 | Mar 20, 2025 |
| Mar 20, 2025 | Edward M. Kaye MD CEO | AGrant or award Employee Stock Option (Right to Buy)derivative | +216,000 | $0.00 | $0 | 216,000 | Mar 20, 2025 |
| Mar 20, 2025 | Jonathan Allan GENERAL COUNSEL & CORP SEC | AGrant or award Employee Stock Option (Right to Buy)derivative | +72,000 | $0.00 | $0 | 72,000 | Mar 20, 2025 |
| Mar 20, 2025 | Edward M. Kaye MD CEO | AGrant or award Restricted Stock Unitsderivative | +144,000 | $0.00 | $0 | 144,000 | Mar 20, 2025 |
| Mar 20, 2025 | Jonathan Allan GENERAL COUNSEL & CORP SEC | AGrant or award Restricted Stock Unitsderivative | +48,000 | $0.00 | $0 | 48,000 | Mar 20, 2025 |
| Mar 15, 2025 | Jonathan Allan GENERAL COUNSEL & CORP SEC | MOption exercise Common Stock | +7,475 | $0.00 | $0 | 29,776 | Mar 18, 2025 |
| Mar 15, 2025 | Edward M. Kaye MD CEO | MOption exercise Common Stock | +35,500 | $0.00 | $0 | 132,385 | Mar 18, 2025 |
| Mar 15, 2025 | Jonathan Allan GENERAL COUNSEL & CORP SEC | MOption exercise Common Stock | +6,000 | $0.00 | $0 | 35,776 | Mar 18, 2025 |
| Mar 15, 2025 | Edward M. Kaye MD CEO | MOption exercise Common Stock | +26,250 | $0.00 | $0 | 158,635 | Mar 18, 2025 |
| Mar 15, 2025 | Jonathan Allan GENERAL COUNSEL & CORP SEC | MOption exercise Restricted Stock Unitsderivative | -7,475 | $0.00 | $0 | 14,950 | Mar 18, 2025 |
| Mar 15, 2025 | Edward M. Kaye MD CEO | MOption exercise Restricted Stock Unitsderivative | -35,500 | $0.00 | $0 | 71,000 | Mar 18, 2025 |
| Mar 15, 2025 | Edward M. Kaye MD CEO | MOption exercise Restricted Stock Unitsderivative | -26,250 | $0.00 | $0 | 78,750 | Mar 18, 2025 |
| Mar 15, 2025 | Jonathan Allan GENERAL COUNSEL & CORP SEC | MOption exercise Restricted Stock Unitsderivative | -6,000 | $0.00 | $0 | 18,000 | Mar 18, 2025 |
| Dec 30, 2024 | Edward M. Kaye MD CEO | MOption exercise Common Stock | +35,000 | $0.60 | $21k | 96,885 | Jan 2, 2025 |
| Dec 30, 2024 | Edward M. Kaye MD CEO | MOption exercise Employee Stock Option (Right to Buy)derivative | -35,000 | $0.00 | $0 | 567,801 | Jan 2, 2025 |
| Dec 23, 2024 | Skorpios Trust owner | SOpen-market sale Common Stockindirect: See Footnote | -2,000,000 | $11.50 | $23M | 6,906,181 | Dec 27, 2024 |
| Dec 9, 2024 | Jonathan Allan GENERAL COUNSEL & CORP SEC | SOpen-market sale Common Stock10b5-1 | -12,114 | $13.69 | $166k | 23,028 | Dec 11, 2024 |
| Dec 9, 2024 | Edward M. Kaye MD CEO | SOpen-market sale Common Stock | -6,786 | $12.99 | $88k | 61,885 | Dec 11, 2024 |
| Dec 9, 2024 | Barry Ticho CHIEF MEDICAL OFFICER | SOpen-market sale Common Stock | -2,586 | $12.99 | $34k | 44,746 | Dec 11, 2024 |
| Dec 9, 2024 | Jonathan Allan GENERAL COUNSEL & CORP SEC | SOpen-market sale Common Stock10b5-1 | -1,552 | $12.99 | $20k | 21,476 | Dec 11, 2024 |
| Dec 3, 2024 | Edward M. Kaye MD CEO | MOption exercise Common Stock | +26,250 | $0.00 | $0 | 74,841 | Dec 10, 2024 |
| Dec 6, 2024 | Barry Ticho CHIEF MEDICAL OFFICER | SOpen-market sale Common Stock | -13,945 | $12.78 | $178k | 47,332 | Dec 10, 2024 |
| Dec 6, 2024 | Edward M. Kaye MD CEO | SOpen-market sale Common Stock | -6,170 | $12.78 | $79k | 68,671 | Dec 10, 2024 |
| Dec 6, 2024 | Jonathan Allan GENERAL COUNSEL & CORP SEC | SOpen-market sale Common Stock | -9,696 | $12.78 | $124k | 35,142 | Dec 10, 2024 |
| Dec 3, 2024 | Edward M. Kaye MD CEO | AGrant or award Performance Stock Unitsderivative | +52,500 | $0.00 | $0 | 52,500 | Dec 10, 2024 |
| Dec 3, 2024 | Edward M. Kaye MD CEO | MOption exercise Performance Stock Unitsderivative | -26,250 | $0.00 | $0 | 26,250 | Dec 10, 2024 |
| Dec 3, 2024 | Jonathan Allan GENERAL COUNSEL & CORP SEC | MOption exercise Common Stock | +6,000 | $0.00 | $0 | 44,838 | Dec 5, 2024 |
| Dec 3, 2024 | Edward M. Kaye MD CEO | MOption exercise Common Stock | +26,500 | $0.00 | $0 | 75,091 | Dec 5, 2024 |
| Dec 3, 2024 | Barry Ticho CHIEF MEDICAL OFFICER | MOption exercise Common Stock | +10,000 | $0.00 | $0 | 61,277 | Dec 5, 2024 |
| Dec 3, 2024 | Jonathan Allan GENERAL COUNSEL & CORP SEC | AGrant or award Performance Stock Unitsderivative | +12,000 | $0.00 | $0 | 12,000 | Dec 5, 2024 |
| Dec 3, 2024 | Edward M. Kaye MD CEO | AGrant or award Performance Stock Unitsderivative | +53,000 | $0.00 | $0 | 53,000 | Dec 5, 2024 |
| Dec 3, 2024 | Barry Ticho CHIEF MEDICAL OFFICER | AGrant or award Performance Stock Unitsderivative | +20,000 | $0.00 | $0 | 20,000 | Dec 5, 2024 |
| Dec 3, 2024 | Edward M. Kaye MD CEO | MOption exercise Performance Stock Unitsderivative | -26,500 | $0.00 | $0 | 26,500 | Dec 5, 2024 |
| Dec 3, 2024 | Barry Ticho CHIEF MEDICAL OFFICER | MOption exercise Performance Stock Unitsderivative | -10,000 | $0.00 | $0 | 10,000 | Dec 5, 2024 |
| Dec 3, 2024 | Jonathan Allan GENERAL COUNSEL & CORP SEC | MOption exercise Performance Stock Unitsderivative | -6,000 | $0.00 | $0 | 6,000 | Dec 5, 2024 |
| Dec 1, 2024 | Jonathan Allan GENERAL COUNSEL & CORP SEC | MOption exercise Common Stock | +33,927 | $0.00 | $0 | 38,838 | Dec 3, 2024 |
| Dec 1, 2024 | Edward M. Kaye MD CEO | MOption exercise Common Stock | +21,591 | $0.00 | $0 | 48,591 | Dec 3, 2024 |
| Dec 1, 2024 | Barry Ticho CHIEF MEDICAL OFFICER | MOption exercise Common Stock10b5-1 | +48,792 | $0.00 | $0 | 51,277 | Dec 3, 2024 |
| Dec 2, 2024 | Barry Ticho CHIEF MEDICAL OFFICER | MOption exercise Common Stock10b5-1 | +10,000 | $0.60 | $6,000 | 61,277 | Dec 3, 2024 |
| Dec 1, 2024 | Jonathan Allan GENERAL COUNSEL & CORP SEC | MOption exercise Restricted Stock Unit (RSU)derivative | -33,927 | $0.00 | $0 | 12,357 | Dec 3, 2024 |
| Dec 1, 2024 | Edward M. Kaye MD CEO | MOption exercise Restricted Stock Unit (RSU)derivative | -21,591 | $0.00 | $0 | 4,317 | Dec 3, 2024 |
| Dec 2, 2024 | Barry Ticho CHIEF MEDICAL OFFICER | SOpen-market sale Common Stock10b5-1 | -10,000 | $12.07 | $121k | 51,277 | Dec 3, 2024 |
| Dec 1, 2024 | Barry Ticho CHIEF MEDICAL OFFICER | MOption exercise Restricted Stock Unit (RSU)derivative10b5-1 | -48,792 | $0.00 | $0 | 11,981 | Dec 3, 2024 |
| Dec 2, 2024 | Barry Ticho CHIEF MEDICAL OFFICER | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -10,000 | $0.00 | $0 | 0 | Dec 3, 2024 |
| Nov 1, 2024 | Barry Ticho CHIEF MEDICAL OFFICER | MOption exercise Common Stock10b5-1 | +10,000 | $0.60 | $6,000 | 12,485 | Nov 5, 2024 |
| Nov 1, 2024 | Barry Ticho CHIEF MEDICAL OFFICER | SOpen-market sale Common Stock10b5-1 | -10,000 | $12.68 | $127k | 2,485 | Nov 5, 2024 |
| Nov 1, 2024 | Barry Ticho CHIEF MEDICAL OFFICER | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -10,000 | $0.00 | $0 | 10,000 | Nov 5, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Jonathan AllanGENERAL COUNSEL & CORP SEC
- Jennifer Bursteindirector
- Alexander Cumboceo, president, officer, director
- Seth Loring Harrisondirector
- Edward M. Kaye MDCEO
- Adrian R. Krainerdirector
- Arthur A Levindirector
- Garry E Menzeldirector
- Skorpios Trustowner
- Julie Smithdirector
- Barry TichoCHIEF MEDICAL OFFICER
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.